COVAC-1

BIOLOGICAL3 trials

Sponsors

University Hospital Tuebingen, University of Saskatchewan

Conditions

Immune Deficiency DiseaseSevere Acute Respiratory Syndrome Coronavirus 2Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Phase 1

B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency

CompletedNCT04954469

University Hospital TuebingenImmune Deficiency Disease

Start: 2021-06-30End: 2023-04-30Updated: 2023-08-04

A Clinical Trial of COVAC-1, a COVID-19 Vaccine, in Generally Healthy Adults

WithdrawnNCT05155982

University of SaskatchewanSevere Acute Respiratory Syndrome Coronavirus 2

Start: 2022-06-30End: 2023-10-31Updated: 2022-08-10

A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults

CompletedNCT05693272

University of SaskatchewanSevere Acute Respiratory Syndrome Coronavirus 2 Infection

Start: 2023-01-31End: 2024-06-04Updated: 2024-12-05

Related Papers

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients

Frontiers in Immunology2024-11-262 citations

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

Frontiers in Oncology2024-03-2810 citations

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

2023-08-1816 citations

Abstract CT258: Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency

Cancer Research2022-06-153 citations

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Cancers2021-09-0647 citations